Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q2 2026 · 10-Q
Revenue$11.89M$11.89M+232.3% vs Q2 2025 Net Income-$18.23M-$18.23MN/M vs Q2 2025 EPS Diluted-$0.15-$0.15N/M vs Q2 2025 Operating Income-$18,554,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,674,000N/M Margins · derivedOperating margin-156.0%+1284.5 pt vs Q2 2025
Net margin-153.3%+1334.5 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end